The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isEarly clinical only.
- What to watchBelly pain that spreads to the back.
How UBT251 works
A triple agonist at the GLP-1, GIP and glucagon receptors — the same three-receptor design as retatrutide. The glucagon arm is what separates the triples from the duals: glucagon raises energy expenditure directly rather than only suppressing intake, which is the mechanism the class is betting on for larger weight loss.
Three receptors, and the useful way to think about them is as three separate drugs sharing one syringe. UBT251 is described by its originator as a GLP-1 / GIP / glucagon triple receptor agonist.
The glucagon arm is the one that makes a triple different from a dual, and it is the one that cuts both ways. Glucagon-receptor agonism raises hepatic fat oxidation and whole-body energy expenditure — that is where weight loss beyond a GLP-1's comes from. It also raises hepatic glucose output, which is the opposite of what a diabetes drug wants, and it raises heart rate.
- Injectable
Research on UBT2515 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Human (early clinical, United Biotechnology; rights licensed to Novo Nordisk in 2026).
Human clinical evidence
Early clinical only. A GLP-1 / GIP / glucagon triple agonist from United Biotechnology, with rights licensed to Novo Nordisk in 2026. No phase 3 data.
A licensing deal is a commercial signal, not a clinical one. It says a large company liked the early data enough to pay for it. None of which is public.
Correlative data
Retatrutide is the closest read: same three receptors, same design logic, and considerably further along. The class-wide pattern so far is that the glucagon arm buys additional weight loss and additional gastrointestinal burden.
How the mechanism reads
The glucagon arm is what separates a triple from a dual. GLP-1 and GIP act mostly on intake and insulin handling; glucagon raises energy expenditure directly. That is the bet the whole triple-agonist class is making.
MechanisticLike everything in this class — it goes in its own syringe.
Mechanistic
Sources
- Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.. N Engl J Med 2023 · PMID 37366315
- Coskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept.. Cell Metab 2022 · PMID 35985340
- Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. Lancet 2022 · PMID 36354040
- Robinson LE, Holt TA, Rees K. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis.. BMJ Open 2013 · PMID 23355666
- The United Laboratories International Holdings and Novo Nordisk. Exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist, with phase 1b results quoted in the announcement (not peer-reviewed).. Company announcement, 24 March 2025
- The United Laboratories International Holdings and Novo Nordisk. Announcement of Chinese phase 2 obesity results for UBT251 - 205 patients, 24 weeks (media release; detailed data stated as due at a medical congress, not peer-reviewed).. Company announcement, 24 February 2026
UBT251 safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Medullary thyroid cancer in you or family, or MEN2.
- Pancreatitis history or gallbladder disease.
- Insulin or sulfonylurea use, since three arms lower glucose.
- Resting rapid pulse: the glucagon arm lifts heart rate.
- Wanting solid human data: only early clinical work exists.
What’s expected
- If it behaves like other triples: large appetite fall plus glucagon-driven energy burn.
- Nausea early.
- Raised heart rate.
- Fat and lean mass both fall.
Watch for
- Belly pain that spreads to the back.
- Pounding heart at rest.
- Yellow eyes while using UBT251.
- Dehydration from vomiting.
Labs that tell you it’s working
- Lipase
- HbA1c (Hemoglobin A1c)
- Lipid Panel
- Comprehensive Metabolic Panel (CMP)
UBT251 (vistrutide) is a GLP-1, GIP and glucagon triple agonist in early trials; thinner data reflect timing, not failure.
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
UBT251 FAQ4 common questions
- Is UBT251 approved for human use?
- No. UBT251 is a research compound.
- What is UBT251 researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- Lipase; HbA1c; Lipid Panel; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for UBT251: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



